Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Current Assets (2016 - 2025)

ImmunityBio (IBRX) has disclosed Current Assets for 12 consecutive years, with $329.5 million as the latest value for Q3 2025.

  • On a quarterly basis, Current Assets changed N/A to $329.5 million in Q3 2025 year-over-year; TTM through Sep 2025 was $329.5 million, a N/A change, with the full-year FY2024 number at $184.6 million, down 37.23% from a year prior.
  • Current Assets was $329.5 million for Q3 2025 at ImmunityBio, up from $208.1 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $334.3 million in Q4 2021 to a low of $99.6 million in Q1 2021.
  • A 5-year average of $192.5 million and a median of $190.2 million in 2024 define the central range for Current Assets.
  • Peak YoY movement for Current Assets: skyrocketed 199.29% in 2021, then tumbled 57.95% in 2022.
  • ImmunityBio's Current Assets stood at $334.3 million in 2021, then crashed by 57.95% to $140.6 million in 2022, then skyrocketed by 109.2% to $294.1 million in 2023, then tumbled by 37.23% to $184.6 million in 2024, then skyrocketed by 78.51% to $329.5 million in 2025.
  • Per Business Quant, the three most recent readings for IBRX's Current Assets are $329.5 million (Q3 2025), $208.1 million (Q2 2025), and $109.2 million (Q1 2025).